Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, People's Republic of China.
Department of Oncology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Cancer Control. 2021 Jan-Dec;28:1073274821989301. doi: 10.1177/1073274821989301.
Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.
表皮生长因子受体（EGFR）在大多数鼻咽癌（NPC）样本中高度表达，与不良预后相关。因此，靶向 EGFR 可能是改善患者预后的一种有前途的策略。尼妥珠单抗是一种人源化抗 EGFR 单克隆抗体。最近，越来越多的证据表明，尼妥珠单抗联合诱导化疗、放疗或同期放化疗可使 NPC 患者获益。此外，这些方案的副作用是可以耐受的。在这篇综述中，我们重点关注尼妥珠单抗在 NPC 临床试验中的最新数据。
